A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-12 year…
Ended Awarded Last action
- Contract number
- HHSN26100009
- Awardee
-
University Of Arizona UEI ED44Y3W6P7B9 Part of State Of Arizona
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,843,821
Award facts
- Opportunity
-
- N01CN0501469 Solicitation number
- Contract value 100% obligated
- $2,843,821.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Tucson, AZ 85719, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Change Order | $139,720 | |
| Exercise an Option | $1,544,461 | |
| Original award | $1,159,640 |
About this award
This federal contract award, valued at $2,843,821, was issued by the National Cancer Institute to the University of Arizona, doing business as the Arizona Board of Regents, for a prospective Phase IIa clinical trial to assess the immunogenicity of a nonavalent prophylactic HPV vaccine using a prime and deferred-booster dosing schedule in 9-12 year old girls. The award is part of the Cancer Prevention Agent Development Program, which supports early-phase clinical trials. This is not a set-aside contract. The University of Arizona is the prime contractor, leveraging its capabilities as a major research university to conduct the clinical study and support the National Cancer Institute's mission. The contract has an ultimate completion date of June 30, 2023.
Description
A prospective, single-arm, open-label, non-randomized, phase IIA trial of a nonavalent prophylactic HPV vaccine to assess immunogenicity of a prime and deferred-booster dosing schedule among 9-12 year old girls
Quick answers
Who was awarded contract HHSN26100009?
HHSN26100009 was awarded to University Of Arizona by National Cancer Institute (National Institutes of Health) on September 1, 2015.
How much is contract HHSN26100009 worth?
The government has obligated $2,843,821 on HHSN26100009.
Is contract HHSN26100009 an order under another contract?
Yes. HHSN26100009 is a delivery order under HHSN261201200031I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100009 competed?
The extent of competition for HHSN26100009 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award